Literature DB >> 29237614

Toxicity of long-term use of proton pump inhibitors in children.

Pauline De Bruyne1, Shinya Ito2,3.   

Abstract

Proton pump inhibitor (PPI) use is becoming increasingly common. Although the toxicity profiles of PPIs are not well understood particularly in children, PPIs have been associated with increased risks of gastrointestinal and respiratory tract infection, vitamin B12 deficiency, hypomagnesaemia, bone fractures, and rebound hyperacidity after discontinuation. Prescribers should take into account that PPI uses pose toxicity risks, which remain to be fully characterised in infants and children. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  adverse events; children; gastroesophageal reflux; proton pump inhibitors; safety

Mesh:

Substances:

Year:  2018        PMID: 29237614     DOI: 10.1136/archdischild-2017-314026

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  17 in total

1.  CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections.

Authors:  Christiana J Bernal; Ida Aka; Robert J Carroll; Joseph R Coco; John J Lima; Sari A Acra; Dan M Roden; Sara L Van Driest
Journal:  Pediatrics       Date:  2019-11-07       Impact factor: 7.124

2.  Chronic Cough and Gastroesophageal Reflux in Children: CHEST Guideline and Expert Panel Report.

Authors:  Anne B Chang; John J Oppenheimer; Peter J Kahrilas; Ahmad Kantar; Bruce K Rubin; Miles Weinberger; Richard S Irwin
Journal:  Chest       Date:  2019-04-16       Impact factor: 9.410

3.  Vitamin B12 deficiency in children from Northern India: Time to reconsider nutritional handicaps.

Authors:  Swati Umasanker; Rahul Bhakat; Sonalika Mehta; Vyas Kumar Rathaur; Prashant Kumar Verma; N K Bhat; Manisha Naithani; Swathi Chacham
Journal:  J Family Med Prim Care       Date:  2020-09-30

4.  Overtesting and overtreatment-statement from the European Academy of Paediatrics (EAP).

Authors:  Ketil Størdal; Corinne Wyder; Andreas Trobisch; Zachi Grossman; Adamos Hadjipanayis
Journal:  Eur J Pediatr       Date:  2019-09-10       Impact factor: 3.183

Review 5.  Irritable bowel syndrome in children: Current knowledge, challenges and opportunities.

Authors:  Niranga Manjuri Devanarayana; Shaman Rajindrajith
Journal:  World J Gastroenterol       Date:  2018-06-07       Impact factor: 5.742

6.  Electrolyte disturbances in children receiving omeprazole for gastroesophageal reflux disease.

Authors:  Fatemeh Famouri; Forough Derakhshani; Yahya Madihi; Armindokht Shahsanai
Journal:  J Res Med Sci       Date:  2020-11-26       Impact factor: 1.852

7.  Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children.

Authors:  Yun-Han Wang; Viktor Wintzell; Jonas F Ludvigsson; Henrik Svanström; Björn Pasternak
Journal:  JAMA Pediatr       Date:  2020-06-01       Impact factor: 16.193

8.  Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial.

Authors:  Piotr Dziechciarz; Katarzyna Krenke; Hania Szajewska; Andrea Horvath
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2020-05-08

9.  Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.

Authors:  Emily J Cicali; Kathryn Blake; Yan Gong; Edward B Mougey; Hadeel Al-Atrash; Nancy Chambers; Jolanda Denham; Jonathan Evans; Donald E George; Roberto Gomez; Pablo Palomo; Salik Taufiq; Julie A Johnson; John J Lima; James P Franciosi
Journal:  Clin Transl Sci       Date:  2018-10-20       Impact factor: 4.689

10.  Natural history of gastroesophageal reflux in infancy: new data from a prospective cohort.

Authors:  Marlène Curien-Chotard; Prévost Jantchou
Journal:  BMC Pediatr       Date:  2020-04-07       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.